Design of oleanolic acid-based hybrid compounds as potential pharmaceutical scaffolds

Show simple item record

dc.contributor.author Khwaza, Vuyolwethu
dc.contributor.author Oyedeji, Opeoluwa Oyehan
dc.contributor.author Aderibigbe, Blessing Atim
dc.contributor.author Morifi, Eric
dc.contributor.author Fonkui, Youmbi Thierry
dc.contributor.author Ndinteh, Derek Tantoh
dc.contributor.author Nell, Margo Judith
dc.contributor.author Steenkamp, Vanessa
dc.date.accessioned 2023-02-10T12:43:06Z
dc.date.available 2023-02-10T12:43:06Z
dc.date.issued 2022-01
dc.description.abstract BACKGROUND : Infectious diseases, as well as cancer, are the leading causes of death worldwide. Drug resistance usually results in their treatment requiring a combination of two or more drugs. OBJECTIVE : Oleanolic-based hybrid compounds were prepared via esterification and characterized using FTIR, NMR and LC-MS. In vitro antibacterial and in vitro cytotoxicity studies were performed. METHODS : Oleanolic acid was hybridized with selected known pharmaceutical scaffolds via the carboxylic acid functionality in order to develop therapeutics with increased biological activity. Antibacterial activity was determined using the micro-dilution assay against selected Gram-positive and Gram-negative bacteria and cytotoxicity using the sulforhodamine B assay. RESULTS : Compound 8 displayed potent antibacterial effect against five strains of bacteria, such as Bacillus subtilis, Staphylococcus aureus, Proteus vulgaris, Klebsiella oxytoca, and Escherichia coli, with MIC values of 1.25, 0.078, 0.078, 1.25, 1.25 mg/mL when compared to the control, oleanolic acid (MIC = 2.5 mg/mL). Furthermore, in vitro cytotoxicity, as determined using the SRB assay, against selected cancer cells revealed that compound 7 was the most cytotoxic on MDA, DU145, and MCF-7 cell lines with IC50 values of 69.87 ± 1.04, 73.2 ± 1.08, and 85.27 ± 1.02 μg/mL, respectively, compared to oleanolic acid with an IC50 > 200 μg/mL. CONCLUSION : Hybridization of oleanolic acid was successful, and further development of these potential antibacterial compounds with reduced cytotoxicity is therefore warranted. en_US
dc.description.department Pharmacology en_US
dc.description.librarian hj2023 en_US
dc.description.sponsorship The South African Medical Research Council (Self-Initiated Research), National Research Foundation South African and Govan Mbeki Research and Development Centre (GMRDC), University of Fort Hare. en_US
dc.description.uri https://benthamscience.com/journals/letters-in-drug-design-and-discovery en_US
dc.identifier.citation Khwaza, V., Oyedeji, O.O., Aderibigbe, B.A. et al. 2022, 'Design of oleanolic acid-based hybrid compounds as potential pharmaceutical scaffolds', Letters in Drug Design and Discovery, vol. 19, no. 1, pp. 10-19, doi : 10.2174/1570180818666210604112451. en_US
dc.identifier.issn 1570-1808 (print)
dc.identifier.issn 1875-628X (online)
dc.identifier.other 10.2174/1570180818666210604112451
dc.identifier.uri https://repository.up.ac.za/handle/2263/89414
dc.language.iso en en_US
dc.publisher Bentham Science Publishers en_US
dc.rights © 2021 Bentham Science Publishers en_US
dc.subject 4-aminosalicylic acid en_US
dc.subject Oleanolic acid en_US
dc.subject Antibacterial en_US
dc.subject Anticancer en_US
dc.subject Curcumin en_US
dc.subject Hybrid compounds en_US
dc.title Design of oleanolic acid-based hybrid compounds as potential pharmaceutical scaffolds en_US
dc.type Postprint Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record